Stocks · Healthcare · Biotechnology
Coherus Oncology, Inc. CHRS
$1.16 +0.00% Close, Oct 2, 2026 · NASDAQ · Market cap $179.2M
Weak trendExpensive vs sector
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin narrowed to -307.4% from -97.7% a year earlier.
- The diluted share count rose 33.4% in a year.
- Revenue over the last four quarters was $50.9M, down 64.3% from a year earlier, accelerating from -76.3% a quarter earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 8%
- Revenue growth, 3-year CAGRBottom 3%
- Revenue growth accelerationTop 12%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 6%
- Gross marginBottom 49%
- Operating marginBottom 21%
- Accruals (lower is better)Bottom 2%
- Interest coverBottom 29%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 8%
- Free-cash-flow yieldBottom 1%
- EBITDA / enterprise valueBottom 5%
- Sales / enterprise valueTop 33%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 28%
- 6-month returnBottom 14%
- 1-year return vs S&P 500Bottom 24%
- Distance from 52-week highBottom 21%
- Trend checklist (0–4)Bottom 14%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 43%
- Consecutive EPS beatsTop 25%
- Share of analysts rating BuyTop 40%
- Upside to consensus price targetTop 6%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 24%
- Maximum drawdown, 3 yearsBottom 28%
- Beta vs S&P 500 (lower is better)Bottom 43%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -76.3% | -64.3% | ↑ |
| Gross margin | 56.1% | 63.6% | ↑ |
| Operating margin | -97.7% | -307.4% | ↓ |
| FCF margin | -74.2% | -478.9% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -64.3% | -76.3% | ↑ | Bottom 8% |
| Gross margin | 63.6% | 56.1% | ↑ | Bottom 49% |
| Operating margin | -307.4% | -97.7% | ↓ | Bottom 21% |
| Net margin | -257.1% | -111.6% | ↓ | — |
| Free-cash-flow margin | -478.9% | -74.2% | ↓ | — |
| Return on invested capital | -135.4% | — | Bottom 6% | |
| Revenue growth, 3-year CAGR | -41.5% | — | Bottom 3% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 59.1%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 42.3%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -23.8 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -17.2×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -64.38%
- Shareholder yield
- -64.38%
- Share count change, 1 year
- +33.4%
- Share count change, 3-year CAGR
- +21.1%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 3
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- +7.5%
- Average 2-day reaction, last 8
- +1.4%
- Positive 20 days after report
- 2 of 8
Analysts
- Consensus price target
- $6.02
- Target vs current price
- +419.0%
- Analysts with a rating
- 17
- Share rating Buy or Strong Buy
- 82%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | +24.0% | -2.0% | -18.2% | -7.4% | — |
| May 11, 2026 | +5.1% | +11.4% | -10.3% | -18.9% | -17.1% |
| Mar 9, 2026 | +4.2% | +6.0% | -10.4% | -8.2% | -16.5% |
| Nov 6, 2025 | -3.1% | -5.1% | -13.4% | -21.7% | +41.4% |
| Aug 7, 2025 | -9.7% | -3.5% | +9.1% | +43.1% | +85.7% |
| May 12, 2025 | -12.9% | +5.3% | -21.4% | -11.8% | -5.5% |
| Mar 10, 2025 | -340.0% | +0.0% | -11.5% | -24.8% | -24.8% |
| Nov 6, 2024 | +93.9% | -1.0% | +12.7% | +133.9% | +58.7% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.19 | -$0.25 | +24.0% | $14.3M |
| May 11, 2026 | -$0.25 | -$0.26 | +5.1% | $12.3M |
| Mar 9, 2026 | -$0.34 | -$0.36 | +4.2% | $12.7M |
| Nov 6, 2025 | -$0.33 | -$0.32 | -3.1% | $11.6M |
| Aug 7, 2025 | -$0.34 | -$0.31 | -9.7% | $10.3M |
| May 12, 2025 | -$0.35 | -$0.31 | -12.9% | $7.6M |
| Mar 10, 2025 | -$0.44 | -$0.10 | -340.0% | $54.1M |
| Nov 6, 2024 | -$0.01 | -$0.16 | +93.9% | $70.8M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 2.63× | — | — | Top 33% |
| Free-cash-flow yield | -136.10% | — | — | Bottom 1% |
| Earnings yield | -87.93% | — | — | Bottom 8% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -6.0%
- 200-day average slope (20 days)
- +0.1%
- Distance from 50-day average
- -12.1%
- Distance from 200-day average
- -26.2%
- RSI (14)
- 41.0
- Relative volume
- 0.87×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 73.6%
- Volatility vs own 5-year history
- 35th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.24
- Correlation with S&P 500
- 0.21
- Current drawdown from 1-year high
- -53.8%
- Maximum drawdown, 3 years
- -82.7%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jan 27, 2021 | Nov 4, 2024 | -96.9% | 949 days | Not yet recovered |
| Oct 13, 2020 | Oct 21, 2020 | -12.2% | 6 days | 29 days (Dec 2, 2020) |
| Dec 4, 2020 | Dec 28, 2020 | -11.3% | 15 days | 18 days (Jan 25, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $179.2M
- EPS, diluted (TTM)
- -$1.02
- Revenue (TTM)
- $50.9M
- 52-week range
- $1.09 – $2.62
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $326.6M | $211.0M | $257.2M | $267.0M | $42.2M |
| Gross profit | $269.0M | $141.0M | $98.3M | $149.4M | $24.4M |
| Operating income | -$263.9M | -$256.9M | -$203.2M | -$111.7M | -$179.5M |
| Net income | -$287.1M | -$291.8M | -$237.9M | $28.5M | -$170.3M |
| EPS (diluted) | -$3.81 | -$3.76 | -$2.53 | $0.25 | -$1.45 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $70.8M | $54.1M | $7.6M | $10.3M | $11.6M | $12.7M | $12.3M | $14.3M |
| Net income | -$10.8M | -$50.7M | -$56.6M | -$41.3M | -$35.1M | -$37.3M | -$37.9M | -$20.6M |
| EPS (diluted) | -$0.09 | -$0.44 | -$0.49 | -$0.39 | -$0.30 | -$0.31 | -$0.28 | -$0.13 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$37.4M | -$241.1M | -$174.9M | -$20.4M | -$138.5M |
| Capital expenditure | -$1.3M | -$2.0M | -$286,000 | $0 | $0 |
| Free cash flow | -$38.7M | -$243.2M | -$175.2M | -$20.4M | -$138.5M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $40.9M | $6.4M | $74.2M | $1.5M | $8.2M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $105.3M
- Total assets
- $191.2M
- Total liabilities
- $130.3M
- Total debt
- $37.7M
- Net debt
- -$45.2M
- Shareholders’ equity
- $60.8M
As of Jun 30, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 22,848,985
- Days to cover
- 32.76
- Change vs previous report
- -4.5%
FINRA short interest, settlement date Sep 15, 2026.